- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2520-1026
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The PD-1:PD-L1 axis in Inflammatory Arthritis ; volume:5 ; number:1 ; day:11 ; month:1 ; year:2021 ; pages:1-10 ; date:12.2021
BMC Rheumatology ; 5, Heft 1 (11.1.2021), 1-10, 12.2021
- Urheber
-
Canavan, Mary
Floudas, Achilleas
Veale, Douglas J.
Fearon, Ursula
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41927-020-00171-2
- URN
-
urn:nbn:de:101:1-2021020610533122315623
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Canavan, Mary
- Floudas, Achilleas
- Veale, Douglas J.
- Fearon, Ursula
- SpringerLink (Online service)
Ähnliche Objekte (12)
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Research progress and challenges of the PD-1/PD-L1 axis in gliomas
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Research progress and challenges of the PD-1/PD-L1 axis in gliomas
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Research progress and challenges of the PD-1/PD-L1 axis in gliomas
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors